Centre de recherche Saint-Louis
Research / Science organisation
Location:
Québec,
Canada (CA)
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial (2025)
Tsianakas A, Passeron T, Magnolo N, Blume-Peytavi U, Kelly V, Day I, Serrao R, et al.
Journal article